ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices in Japan. The company offers Altat for the treatment of peptic ulcer and gastritis; Prostal drugs for the treatment of prostatic hypertrophy and cancer; Lipidil for the treatment of hyperlipidemia; Thyradin, a drug for the treatment of thyroid disease; Ange, an oral contraceptive agent; and Menoaid Combipatch, a climacteric syndrome treatment. It is also developing L-105 for the treatment of hepatic encephalopathy; AKP-501, a fertility treatment with follicle stimulating hormone preparation of recombinant DNA as an active agent; and CDB-2914, a uterine leiomyomata treatment. ASKA Pharmaceutical Co., Ltd. has research and development agreement with Ribomic Inc. for drug discovery research and development. The company was founded in 1920 and is headquartered in Tokyo, Japan.
Research context
ASKA Pharmaceutical Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
ASKA Pharmaceutical Holdings Co., Ltd is currently in a long term uptrend where the price is trading 0.7% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
ASKA Pharmaceutical Holdings Co., Ltd's total revenue rose by 9.0% to $16B since the same quarter in the previous year.
Its net income has increased by 84.6% to $899M since the same quarter in the previous year.
Based on the above factors, ASKA Pharmaceutical Holdings Co., Ltd gets an overall score of 4/5.